What are the specific side effects of lapatinib/telisa

Lapatinib (Lapatinib) is a commonly used oral targeted drug for patients with HER2-positive breast cancer. Although it has significant efficacy, it may still have a variety of side effects during clinical use, which requires high attention and active management. The most common adverse reactions are concentrated in the gastrointestinal system and include diarrhea, nausea, vomiting, decreased appetite, and epigastric discomfort. Diarrhea is the most prominent problem with lapatinib use and may sometimes be moderate to severe, requiring intervention with oral rehydration, antidiarrheal drugs, or dose adjustment. Diarrhea that is not treated promptly may lead to dehydration, electrolyte imbalance, and weight loss, which can have a significant impact on patients' quality of life and treatment compliance.

Cardiotoxicity is also a focus of clinical safety concerns of lapatinib. HER2 receptor plays an important regulatory role in cardiomyocytes, so drug inhibition may lead to a decrease in left ventricular ejection fraction and even an increased risk of heart failure. Before starting treatment, patients should undergo an assessment of cardiac function, including electrocardiography and echocardiography. During treatment, cardiac function indicators need to be monitored regularly, especially for patients with a history of cardiovascular disease. If symptoms such as palpitations, dyspnea, or fatigue occur, the dose should be adjusted or medication interrupted in a timely manner.

Abnormal liver function is also a common side effect, manifested as an increase in serum aminotransferases, especially in patients who are combined with other hepatic metabolism drugs or who take them for a long time. Therefore, patients need to regularly monitor liver function indicators during medication, and adjust the dose or temporarily discontinue medication if necessary. In addition, electrolyte abnormalities such as rash, hand-foot syndrome, fatigue, hypocalcemia, and hypomagnesemia also occur in some patients and need to be managed through symptom monitoring and symptomatic treatment. Rarely, lapatinib may cause interstitial lung disease or respiratory symptoms, but the incidence is relatively low.

Clinical studies have shown that although the side effects of lapatinib are diverse, most are controllable and reversible. Through standardized dose management, early symptom recognition and timely intervention, most patients can safely complete the treatment cycle, thereby maximizing the anti-tumor effect.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html